Sarepta Therapeutics to Share Clinical Update for SRP-5051, its Investigational PPMO for the Treatment of Duchenne Muscular D...
December 04 2020 - 4:05PM
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision
genetic medicine for rare diseases, today announced that on Monday,
Dec. 7, 2020 at 8:30 am Eastern Time (ET), it will host a webcast
and conference call to present interim data from the MOMENTUM
study, a multiple-ascending dose clinical trial of SRP-5051 for the
treatment of Duchenne muscular dystrophy. SRP-5051 is the first
investigational treatment using Sarepta’s next-generation PPMO
platform, which is designed around a proprietary cell-penetrating
peptide conjugated to Sarepta’s phosphorodiamidate morpholino
oligomer (PMO) backbone with the goal of increasing drug
concentration in muscle tissue.
The presentation will be webcast live under the
investor relations section of Sarepta's website at
https://investorrelations.sarepta.com/events-presentations and
slides will be archived there following the call for one year.
Please connect to Sarepta's website several minutes prior to the
start of the broadcast to ensure adequate time for any software
download that may be necessary. The conference call may be accessed
by dialing (844) 534-7313 for domestic callers and (574) 990-1451
for international callers. The passcode for the call is 6382259.
Please specify to the operator that you would like to join the
"Sarepta-hosted Clinical Update for MOMENTUM call."
About Sarepta Therapeutics
At Sarepta, we are leading a revolution in precision genetic
medicine and every day is an opportunity to change the lives of
people living with rare disease. The Company has built an
impressive position in Duchenne muscular dystrophy (DMD) and in
gene therapies for limb-girdle muscular dystrophies (LGMDs),
mucopolysaccharidosis type IIIA, Charcot-Marie-Tooth (CMT), and
other CNS-related disorders, with more than 40 programs in various
stages of development. The Company’s programs and research focus
span several therapeutic modalities, including RNA, gene therapy
and gene editing. For more information, please
visit www.sarepta.com or follow us on Twitter, LinkedIn,
Instagram and Facebook.
Internet Posting of
Information
We routinely post information that may be
important to investors in the 'Investors' section of our website
at www.sarepta.com. We encourage investors and potential
investors to consult our website regularly for important
information about us.
Source: Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. Investors: Ian Estepan,
617-274-4052, iestepan@sarepta.com
Media: Tracy Sorrentino, 617-301-8566,
tsorrentino@sarepta.com
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sarepta Therapeutics (NASDAQ:SRPT)
Historical Stock Chart
From Apr 2023 to Apr 2024